A pivotal 2023 study examining sucralose, the widely used artificial sweetener marketed as Splenda®, ignited a significant debate concerning its safety. The research, published in the journal Food and Chemical Toxicology, reported that a chemical associated with sucralose, identified as sucralose-6-acetate, demonstrated genotoxic properties in laboratory experiments, meaning it could damage DNA. Furthermore, the study indicated that this compound disrupted a laboratory model of the intestinal lining. These findings, while conducted under controlled laboratory conditions, prompted questions about the potential health implications of sucralose consumption.
The initial study’s conclusions, particularly regarding the potential for DNA damage, quickly garnered attention from both the scientific community and the public. Researchers highlighted that sucralose-6-acetate could be present in commercial samples of sucralose as an impurity, with concentrations up to 0.67% detected in some analyses. This discovery fueled concerns that even seemingly innocuous consumption of sucralose-sweetened products could inadvertently expose individuals to a substance with genotoxic potential.
However, the narrative surrounding sucralose’s safety is far from monolithic. Subsequent scientific evaluations and a comprehensive European safety assessment have introduced crucial context, challenging the direct extrapolation of these laboratory findings to real-world human health risks. These later analyses have offered a more nuanced perspective, scrutinizing the formation of sucralose-6-acetate during digestion and ultimately leading to regulatory conclusions that uphold the sweetener’s safety under its current authorized uses.
The Genesis of the Concern: Sucralose-6-Acetate in the Spotlight
The 2023 investigation zeroed in on sucralose-6-acetate, a chemical distinct from sucralose itself but structurally related. The research team, led by Susan Schiffman, an adjunct professor in the joint department of biomedical engineering at North Carolina State University and the University of North Carolina at Chapel Hill, proposed that sucralose-6-acetate could form during the manufacturing process of sucralose and persist as an impurity in the final product. This impurity was detected in commercial sucralose samples, raising immediate questions about the purity and safety of the widely consumed sweetener.
This research built upon earlier work by the same team, published in 2018. In that study, researchers observed compounds that dissolved in fat in the urine and feces of rats that had been administered sucralose. The team interpreted these findings as evidence that sucralose was undergoing chemical alteration within the animals’ bodies. Sucralose-6-acetate was later identified as one of the key compounds of interest in this subsequent investigation. It is critical to note that these earlier findings were based on animal research and did not directly demonstrate the same metabolic transformations occurring in humans.
"Our new work establishes that sucralose-6-acetate is genotoxic," Professor Schiffman stated upon the release of the 2023 findings. "We also found that trace amounts of sucralose-6-acetate can be found in off-the-shelf sucralose, even before it is consumed and metabolized." This assertion suggested that the potential risks were not solely linked to metabolic processes but could also stem from the presence of the impurity itself in the consumable product.
Deconstructing the Laboratory Findings: Genotoxicity and Gut Barrier Integrity
The core of the 2023 study involved laboratory experiments designed to assess the potential harm of sucralose-6-acetate. Researchers exposed cultured human blood cells to the compound and then examined indicators of genetic damage. These experiments, classified as in vitro, meaning they were conducted outside of a living organism, aimed to identify if sucralose-6-acetate possessed the inherent capacity to harm genetic material. The team reported results consistent with genotoxicity, observing patterns suggestive of DNA strand breaks.
Professor Schiffman elaborated on these findings: "In short, we found that sucralose-6-acetate is genotoxic, and that it effectively broke up DNA in cells that were exposed to the chemical." This direct observation of DNA damage in a laboratory setting was a significant point of concern.
However, a critical distinction exists between a laboratory-observed effect and a demonstrable health risk in humans. While exposing cells directly to a chemical in a controlled environment can reveal a potential hazard, it does not automatically confirm that ingesting a food product containing that chemical will lead to sufficient exposure in human tissues to cause the same damage. The 2023 experiments, therefore, did not establish that ordinary sucralose consumption leads to DNA damage in people.
Beyond genotoxicity, the researchers also investigated the impact of sucralose and sucralose-6-acetate on the intestinal lining, a crucial component of the digestive system that regulates the passage of substances from the gut into the bloodstream. Using a laboratory system that simulated human intestinal tissue, the study found that both sucralose and sucralose-6-acetate impaired the barrier’s integrity under the experimental conditions.
"Other studies have found that sucralose can adversely affect gut health, so we wanted to see what might be happening there," Professor Schiffman explained. "When we exposed sucralose and sucralose-6-acetate to gut epithelial tissues — the tissue that lines your gut wall — we found that both chemicals cause ‘leaky gut.’ Basically, they make the wall of the gut more permeable. The chemicals damage the ‘tight junctions,’ or interfaces, where cells in the gut wall connect to each other." The concept of "leaky gut" suggests increased permeability of the intestinal wall, potentially allowing substances that would normally be eliminated from the body to enter the bloodstream.
Further analysis within the laboratory model explored how exposure to sucralose-6-acetate influenced gene activity in intestinal cells. The researchers reported increased activity in genes associated with oxidative stress, inflammation, and carcinogenicity. These findings described cellular responses observed in a laboratory setting. It is important to reiterate that increased activity in genes linked to cancer does not equate to the development of cancer, just as increased permeability in cultured tissue does not prove that normal sweetener use causes an intestinal disorder in humans.
Challenging the Digestion Hypothesis and Introducing Regulatory Scrutiny
A significant point of contention that emerged following the 2023 study concerned the claim that sucralose metabolizes into harmful compounds during digestion. In its comprehensive review, the European Food Safety Authority (EFSA) noted that the compounds detected in the earlier rat study could have been impurities already present in the sucralose administered. Consequently, their appearance in urine and feces did not necessarily confirm that metabolism was the source of their production. This observation cast doubt on the direct link between sucralose consumption and the formation of sucralose-6-acetate within the body.
The Threshold of Concern: Contextualizing Exposure Levels
The researchers behind the 2023 study also raised concerns about the quantity of sucralose-6-acetate that individuals might consume unknowingly. Professor Schiffman cited the European Food Safety Authority’s threshold of toxicological concern (TTC) for genotoxic substances, which is set at 0.15 micrograms per person per day. The study suggested that the trace amounts of sucralose-6-acetate found in a single, daily sucralose-sweetened beverage could exceed this threshold, even without considering any potential formation of the compound through metabolism.
However, this comparison requires careful qualification. A TTC is a conservative screening tool designed to identify chemicals that warrant further investigation when detailed toxicity data is limited. Exceeding a TTC is not definitive proof of harm; it is an indication for closer scrutiny. Moreover, this threshold is distinct from the acceptable daily intake (ADI) specifically established for sucralose, which is a measure of the amount of a substance that can be consumed daily over a lifetime without appreciable health risk.
Despite these distinctions, the research team maintained that their findings warranted a re-evaluation of sucralose’s safety. "This work raises a host of concerns about the potential health effects associated with sucralose and its metabolites," Professor Schiffman stated in 2023. "It’s time to revisit the safety and regulatory status of sucralose, because the evidence is mounting that it carries significant risks. If nothing else, I encourage people to avoid products containing sucralose. It’s something you should not be eating." This strong warning reflected the researchers’ position at the time of their publication.
The European Food Safety Authority’s 2026 Reassessment: A Definitive Stance
In February 2026, the European Food Safety Authority published a thorough reassessment of sucralose, incorporating the latest scientific evidence, including the 2023 genotoxicity findings. The EFSA panel reaffirmed the established acceptable daily intake (ADI) for sucralose at 15 milligrams per kilogram of body weight per day. This level represents an amount considered safe for daily consumption over a lifetime. The authority concluded that estimated dietary exposure to sucralose remained below this ADI across all assessed population groups.
The EFSA review explicitly considered the reported DNA damage signals associated with sucralose-6-acetate. However, the panel judged the available screening evidence to have limited relevance for their safety assessment. After meticulously weighing laboratory, animal, and other available data, the EFSA concluded that sucralose’s use as a food additive did not present a genotoxicity concern under its currently authorized uses. This comprehensive review provided a significant counterpoint to the initial alarm raised by the 2023 study.
United States Regulatory Stance and Independent Genetic Testing
In the United States, sucralose also continues to be approved as a food sweetener. The Food and Drug Administration (FDA) maintains that its safety assessment encompasses a substantial body of evidence, including over 110 studies specifically addressing potential toxic effects and extensive human clinical research. This aligns with the broader consensus among major regulatory bodies regarding sucralose’s safety.
Further contributing to the scientific discourse, a study published online in August 2026 in Food and Chemical Toxicology evaluated commercial-grade sucralose using a battery of genetic toxicity tests in both cellular models and animals. The authors reported largely negative results across most assays, including tests for mutations and chromosome damage. A separate study involving genetically modified mice also found no significant increase in the mutations being measured.
One specific test, known as a comet assay, did detect signals indicative of DNA damage in several tissues. However, the authors noted complications in interpreting these particular results and concluded that the overall findings did not support a conclusion of genotoxicity. It is noteworthy that several authors of this study had affiliations with Tate & Lyle, a major producer of sucralose, and Intertek, a quality assurance company. While industry involvement does not automatically invalidate findings, it is a relevant contextual factor for scientific evaluation. Critically, this investigation focused on commercial sucralose rather than directly replicating the 2023 experiments with isolated sucralose-6-acetate, addressing related but distinct scientific questions.
Beyond Genotoxicity: Exploring Broader Biological Effects
While the debate surrounding genotoxicity has been prominent, separate research has delved into other potential biological effects of sucralose, such as its influence on appetite regulation and metabolic processes. These studies do not directly address DNA damage but contribute to a holistic understanding of how sucralose interacts with the human body.
A randomized controlled study published in Nature Metabolism in March 2025 involved 75 young adults who consumed drinks containing sucralose, an equivalent amount of sugar, or water on separate occasions. Compared to sugar, sucralose consumption led to increased reported hunger and heightened blood flow in the hypothalamus, a brain region critical for appetite control. When compared to water, sucralose increased hypothalamic blood flow but did not significantly alter hunger ratings. These observed effects were immediate responses and did not provide evidence of lasting weight gain.
More recently, a systematic review published in August 2026 examined 23 randomized controlled trials focusing on sucralose and cardiometabolic outcomes in healthy adults. The review presented mixed results regarding blood sugar regulation, with some studies indicating unfavorable changes while others found no significant effect. The authors of this review expressed concerns about possible metabolic effects, emphasizing that these questions regarding appetite and glucose regulation are distinct from the initial claims about DNA damage.
The Unresolved Question of Heating Sucralose
The EFSA’s 2026 review also highlighted an ongoing concern related to the prolonged exposure of sucralose to high temperatures. Under specific heating conditions, chlorine from sucralose may integrate into other compounds, the health effects of which remain uncertain. This uncertainty led the EFSA panel to withhold confirmation of safety for a proposed expansion of sucralose use in certain baked goods. The review also pointed out that similar uncertainties could arise during home baking or frying, given the variability in temperatures, cooking times, and ingredient quantities. This particular concern pertains to the potential formation of new compounds during heating, rather than confirming the genotoxicity findings associated with sucralose-6-acetate from the 2023 study.
Conclusion: A Nuanced Perspective on Sucralose Safety
In summation, the evidence surrounding sucralose’s safety presents a complex picture. The 2023 study undeniably brought to light potentially significant effects observed in laboratory systems concerning sucralose-6-acetate. However, subsequent, more extensive regulatory reviews and independent scientific investigations have not substantiated the claim that ordinary sucralose consumption leads to the same harm in humans. While questions persist regarding specific compounds, varying exposure conditions, and other potential biological interactions, the overarching regulatory consensus, as articulated by major international bodies like the EFSA, is that sucralose remains safe for its currently authorized uses. The scientific community continues to monitor and research artificial sweeteners, but the initial alarm regarding DNA damage from sucralose consumption has been largely tempered by subsequent, more comprehensive evaluations.
